InvestorsHub Logo
Followers 285
Posts 31200
Boards Moderated 0
Alias Born 07/06/2012

Re: John_Langston post# 100346

Saturday, 03/29/2014 9:56:41 AM

Saturday, March 29, 2014 9:56:41 AM

Post# of 402169

ELTP will get pushed over the weekend


Top O' the early Saturday morning my beautiful ELTPers!!

And what a glorious morning it is in the land of ELTP. I hear tell little old Elite has hired the beautiful Ms.Barbara Ellison since I've been away. I particularly like her previous international experience with regulatory affairs. Say anybody think that has anything to do with the Canadian Patent Elite just garnered? Highest opioid revenue generating countries in the World: the United States and Canada. Check and double check. Cha Ching. What's next a European ART patent. Notice the lack of question mark.

http://www.elitepharma.com/patents.asp

And what is holding up the FDA in terms of handing Elite its 3rd ART patent? New FDA procedural red tape. Go figure. Guess we know who is gumming up the works for our next pivotal BE study launch. Just put a tax penalty on all company's who illegally short sell stocks and put the proceeds toward additional FDA hires and regulatory affairs. Or should that money actually go to the SEC. The SEC it is.

What does that make for employees now 32?.... with another position: Lead Operator yet to hire? Whew seems only yesterday Elite only had 16 employees and zero products on the market. Now 8 and Isradipine's CBE 30 has been filed. Not a big money maker unless Marty McFly has anything to say about it. Still every million dollar quarterly revenue increase mattes. Help me out BMT what does that make 5 stellar revenue quarters one after the other?

CFP on operations and moving in on R&D costs as I type! Dantrolene, Loxapine, and Hydroxyzine next on the CBE 30 docket. And as the DDoctor has mentioned Hydroxyzine could bring in a little money. What was it $55 million IMS yearly sales per Mylan PR in 2010. We're making tablets...so 12 other tablet makers currently including Watson. Not a killer product but perhaps Elite can garner $4 -6 million on it. Elite used to be CFP minus R&D costs on $4 million alone. Probably more like $6 million now considering all the new infrastructure and machinery Doug Plasche is overseeing.

NOW the Proxy Vote. Interesting situation and clearly Nasrat is playing Chess like a master. He is sending a message IMO. We would like a Big Pharma partner but you best sign on bc the ART Monorail Train is leaving the station and YOU best have a ticket!! ART is coming!!!

With or without YOU!!

Anyone like to see the previous Proxy Vote of 2011 and compare it to the 2014? Here they are. 355,517,558 in 2011 and now they want 995,000,000 shares in 2014. Almost 3 times the amount of AS from 2011 to 2014 IF passed. Well what I can tell you is the PPS at the time of the Proxy Vote in 2011 was .1295. So Elite has tripled their PPS since the previous Proxy Vote. Me I voted YES on the previous proxy and I'm voting YES this time around as well. Let's just hope WE aren't asked for another vote in 2017 unless Elite is sitting squarely on the NASDAQ at $5 a share!

Nasrat is a Master at negotiations and MY BET we hear from him sooner than later regarding the Proxy Vote.

http://www.elitepharma.com/ELTP%20FY2011%20DEF14A.pdf

http://archive.fast-edgar.com//20140318/A8A2N22CZC22L2ZU222S2WZA9L6C2B22Z262/

My BEST as always LONGS. It's GOOD to be back!! smile

Couch
The Helper


Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News